# Zentalis Pharmaceuticals, Inc. (ZNTL) — capital_raise/public_offering [pending]
Source: sec.gov · situation sit_3c5c99dd0c77c9722694 · public 9218722528013734578 · retrieved 2026-08-19T12:10:16.308Z

## Overview
Zentalis Pharmaceuticals, Inc. is a biopharmaceutical company developing oncology and other therapeutic programs; it intends to use net proceeds from the offering to fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostics, and pre-commercial activities.

On August 13, 2026, Zentalis Pharmaceuticals, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc. to offer and sell 23,000,000 shares of common stock at $3.50 per share. The underwriters also received a 30-day option to purchase up to an additional 3,450,000 shares at the same public offering price. The company estimates net proceeds of approximately $75.1 million after deducting underwriting discounts, commissions, and estimated offering expenses. The closing is expected on August 17, 2026, subject to customary closing conditions.

## Terms
- Counterparty: TD Securities (USA) LLC, Guggenheim Securities, LLC, Oppenheimer & Co. Inc. · Consideration: cash · Price/share: $3.5

## Key dates
- Announced 2026-08-14 · Expected close 2026-08-17

## Timeline
- 2026-08-14 · 8-K (0001628280-26-057112): 8-K - Zentalis Pharmaceuticals, Inc. — *Zentalis Pharmaceuticals, Inc. is a biopharmaceutical company developing oncology and other therapeutic programs; it intends to use net proceeds from the offering to fund clinical trials, preclinical studies, regulatory filings, manufacturing, companion diagnostics, and pre-commercial activities.* On August 13, 2026, Zentalis Pharmaceuticals, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC, and Oppenheimer & Co. Inc. to offer and sell 23,000,000 shares of common stock at $3.50 per share. The underwriters also received a 30-day option to purchase up to an additional 3,450,000 shares at the same public offering price. The company estimates net proceeds of approximately $75.1 million after deducting underwriting discounts, commissions, and estimated offering expenses. The closing is expected on August 17, 2026, subject to customary closing conditions.
  https://www.sec.gov/Archives/edgar/data/1725160/0001628280-26-057112.txt

## Citations
- 0001628280-26-057112 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000162828026057112